Latest stories on ZNTL
Zentalis announces median OS data from DENALI Part 1b study
The Fly58 · neutralproduct/pr
Zentalis Validates a Multibillion-Dollar Cancer Market as Aprea Therapeutics Emerges as a Next-Generation Contender
Barchart64 · neutralproduct/pr
Zentalis rises as lead asset extends survival in mid-stage trial for ovarian cancer
Seeking Alpha74 · bullishproduct/pr
H.C. Wainwright reiterates Zentalis stock rating on survival data
Investing.com Analyst Ratings56 · neutralanalyst
Zentalis announces first OS data from DENALI part 1b study
The Fly61 · neutralproduct/pr
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
Business Insider64 · neutralproduct/pr
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
GlobeNewswire64 · neutralproduct/pr
Zentalis Pharmaceuticals Shares Rise After Leerink Assumes Coverage With Outperform Rating
InvestorsHub63 · neutralanalyst
Zentalis assumed at Outperform from Market Perform at Leerink
The Fly61 · neutralanalyst
Why is Zentalis Pharmaceuticals stock up 4% today?
Investing.com Markets57 · neutralgeneral
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
William Blair initiates Zentalis stock with outperform rating
Investing.com Analyst Ratings61 · neutralanalyst
Zentalis initiated with an Outperform at William Blair
The Fly61 · neutralanalyst
Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha56 · neutralgeneral
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Business Insider56 · neutralgeneral
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire56 · neutralgeneral
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Zentalis Pharmaceuticals: Data Due H1 '27 Will Clarify Prospects Of Azenosertib
Seeking Alpha56 · neutralproduct/pr
Zentalis 23M share Spot Secondary priced at $3.50
The Fly28 · bearishgeneral
Zentalis Pharmaceuticals, Inc. (ZNTL) files 8-K
SEC 8-K50 · neutralgeneral
Why is Zentalis Pharmaceuticals stock tumbling today?
Investing.com Markets34 · bearishgeneral